These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 9347203

  • 21. Risk factors for fatal venous thromboembolism in young women: a case-control study.
    Thorogood M, Mann J, Murphy M, Vessey M.
    Int J Epidemiol; 1992 Feb; 21(1):48-52. PubMed ID: 1544757
    [Abstract] [Full Text] [Related]

  • 22. Oral contraceptives and venous thromboembolism: a five-year national case-control study.
    Lidegaard Ø, Edström B, Kreiner S.
    Contraception; 2002 Mar; 65(3):187-96. PubMed ID: 11929640
    [Abstract] [Full Text] [Related]

  • 23. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D, Godsland IF, Worthington M, Felton CV, Proudler AJ, Stevenson JC.
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [Abstract] [Full Text] [Related]

  • 24. Warnings on venous thromboembolism risks may have been premature. New data may lead to change in use of third-generation OCs.
    Contracept Technol Update; 1997 Dec; 18(12):145-8. PubMed ID: 12348219
    [Abstract] [Full Text] [Related]

  • 25. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA, Dinger JC, Assmann A, Minh TD.
    Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
    [Abstract] [Full Text] [Related]

  • 26. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH.
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [Abstract] [Full Text] [Related]

  • 27. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, Meijers JC, Bouma BN, Büller HR, Prins MH, Tans G.
    Lancet; 1999 Dec 11; 354(9195):2036-40. PubMed ID: 10636369
    [Abstract] [Full Text] [Related]

  • 28. On the epidemiology of oral contraceptives and disease.
    Prentice RL, Thomas DB.
    Adv Cancer Res; 1987 Dec 11; 49():285-401. PubMed ID: 3314396
    [Abstract] [Full Text] [Related]

  • 29. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ, Shelton J.
    Contraception; 1997 Mar 11; 55(3):125-9. PubMed ID: 9114999
    [Abstract] [Full Text] [Related]

  • 30. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS, Kaye JA, Russmann S, Jick H.
    Contraception; 2006 Jun 11; 73(6):566-70. PubMed ID: 16730485
    [Abstract] [Full Text] [Related]

  • 31. Effects of oral contraceptives on hemostasis and thrombosis.
    Rosing J, Tans G.
    Am J Obstet Gynecol; 1999 Jun 11; 180(6 Pt 2):S375-82. PubMed ID: 10368524
    [Abstract] [Full Text] [Related]

  • 32. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D, Wildemeersch D, Verougstraete A, Creatsas G.
    Int J Fertil Menopausal Stud; 1995 Jun 11; 40 Suppl 2():73-9. PubMed ID: 8574253
    [Abstract] [Full Text] [Related]

  • 33. Venous thromboembolism among new users of different oral contraceptives.
    Herings RM, Urquhart J, Leufkens HG.
    Lancet; 1999 Jul 10; 354(9173):127-8. PubMed ID: 10408492
    [Abstract] [Full Text] [Related]

  • 34. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec 16; 346(8990):1575-82. PubMed ID: 7500748
    [Abstract] [Full Text] [Related]

  • 35. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J, Mills A.
    Am J Obstet Gynecol; 1997 Sep 16; 177(3):707-15. PubMed ID: 9322646
    [Abstract] [Full Text] [Related]

  • 36. Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinylestradiol and either desogestrel or gestodene in Thai women.
    Koetsawang S, Charoenvisal C, Banharnsupawat L, Singhakovin S, Kaewsuk O, Punnahitanont S.
    Contraception; 1995 Apr 16; 51(4):225-9. PubMed ID: 7796587
    [Abstract] [Full Text] [Related]

  • 37. Oral contraceptives and myocardial infarction: results of the MICA case-control study.
    Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C, Thomas S, Mann R.
    BMJ; 1999 Jun 12; 318(7198):1579-83. PubMed ID: 10364115
    [Abstract] [Full Text] [Related]

  • 38. Newer oral contraceptives and the risk of venous thromboembolism.
    Walker AM.
    Contraception; 1998 Mar 12; 57(3):169-81. PubMed ID: 9617533
    [Abstract] [Full Text] [Related]

  • 39. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O.
    Acta Obstet Gynecol Scand; 1997 Mar 12; 76(3):252-60. PubMed ID: 9093141
    [Abstract] [Full Text] [Related]

  • 40. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD.
    BMJ; 1996 Jan 13; 312(7023):83-8. PubMed ID: 8555935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.